Zobrazeno 1 - 10
of 19
pro vyhledávání: ''
Autor:
Satoshi Yoda, Wafa Malik, Adam Langenbucher, Justin F. Gainor, Sai-Hong Ignatius Ou, Kylie Prutisto-Chang, Ramin Sakhtemani, Jennifer L Peterson, Aaron N. Hata, Alexander Drilon, Andrew Do, Jessica J. Lin, Adam J. Schoenfeld, Viola W. Zhu, Ted William Johnson, Jochen K. Lennerz, Lecia V. Sequist, Noura J. Choudhury, Ibiayi Dagogo-Jack, Subba R. Digumarthy, Christina Falcon, Charlotte E. Lee, Alice T. Shaw, Michael S. Lawrence, Beow Y. Yeap, Jennifer S. Temel, Harper Hubbeling
Publikováno v:
Clin Cancer Res
Purpose: Current standard initial therapy for advanced, ROS proto-oncogene 1, receptor tyrosine kinase fusion (ROS1)-positive (ROS1+) non–small cell lung cancer (NSCLC) is crizotinib or entrectinib. Lorlatinib, a next-generation anaplastic lymphoma
Autor:
Peter S. Hammerman, Jing Yuan, Lesley A. Mathews Griner, Peter Aspesi, Daniel J. McKay, Gwynn Pardee, Hui Qin Wang, Kelli-Ann Monaco, Ribo Guo, Kenneth Crawford, Stephania Widger, Darrin Stuart, Vesselina G. Cooke, Karen Bui, Felipa A. Mapa, Yuji Mishina, Mariela Jaskelioff, Jeffrey A. Engelman, Paul Fordjour, Emma Labrot, Giordano Caponigro, Stacy Higgins, Jessi Ambrose, John Fuller, Jinsheng Liang, John Green, Scott Delach
Publikováno v:
Clinical Cancer Research. 27:2061-2073
Purpose: Targeting RAF for antitumor therapy in RAS-mutant tumors holds promise. Herein, we describe in detail novel properties of the type II RAF inhibitor, LXH254. Experimental Design: LXH254 was profiled in biochemical, in vitro, and in vivo assay
Autor:
Alexander J. Lazar, Roman Groisberg, Vivek Subbiah, Robert E. Brown, Daniella E Portal, Aung Naing, Neeta Somaiah, Maria Alejandra Zarzour, Cynthia E. Herzog, Jason Roszik, Anthony P. Conley, David S. Hong, Shreyaskumar Patel
Publikováno v:
Mol Cancer Ther
Overexpression of transcription factor 3 in alveolar soft part sarcoma(ASPS) results in upregulation of cell proliferation pathways. No standard treatment algorithm exists for ASPS; multikinase inhibitors[tyrosine kinase inhibitor (TKI)] and immune c
Autor:
Heidi M. Namløs, Tale Barøy, Else Munthe, Skyler Mishkin, Susanne Lorenz, Eva W. Stratford, Leonardo A. Meza-Zepeda, Kjetil Boye, Ola Myklebost, Brian Kudlow, Bodil Bjerkehagen
Publikováno v:
Molecular Cancer Therapeutics. 17:2473-2480
Molecular analysis of circulating tumor DNA (ctDNA) has a large potential for clinical application by capturing tumor-specific aberrations through noninvasive sampling. In gastrointestinal stromal tumor (GIST), analysis of KIT and PDGFRA mutations is
Autor:
Max M. Quinn, Xiaoen Wang, Cyril H. Benes, Ashley A. Merlino, Qingsong Liu, Yuyang Li, Peng Gao, Kwok-Kin Wong, Nathanael S. Gray, Feiyang Liu, Fei Li, Yan Liu
Publikováno v:
Cancer Research. 77:5068-5076
Cells lacking the tumor suppressor gene LKB1/STK11 alter their metabolism to match the demands of accelerated growth, leaving them highly vulnerable to stress. However, targeted therapy for LKB1-deficient cancers has yet to be reported. In both Kras/
Autor:
Atsuko Ogino, T. Kosaka, Marzia Capelletti, Jihyun Choi, Hideki Endoh, Junko Tanizaki, Michael J. Eck, Dalia Ercan, Magda Bahcall, Raymond M. Paranal, Geoffrey R. Oxnard, Pasi A. Jänne, Amanda J. Redig, Antonio Calles, Claire E. Repellin, Christine A. Lydon
Publikováno v:
Cancer Research. 77:2712-2721
Insertion mutations in EGFR and HER2 both occur at analogous positions in exon 20. Non–small cell lung cancer (NSCLC) patients with tumors harboring these mutations seldom achieve clinical responses to dacomitinib and afatinib, two covalent quinazo
Autor:
Ravi Salgia
Publikováno v:
Molecular Cancer Therapeutics. 16:555-565
MET or hepatocyte growth factor (HGF) receptor pathway signaling mediates wound healing and hepatic regeneration, with pivotal roles in embryonic, neuronal, and muscle development. However, dysregulation of MET signaling mediates proliferation, apopt
Autor:
Patricia Haney, Michelle Casey, Keith T. Flaherty, Anne O'Hagan, Ademi Santiago-Walker, Dirk Schadendorf, Vicki L. Goodman, Axel Hauschild, Jeffrey J. Legos, Richard F. Kefford, Robert C. Gagnon, Patrick Hwu, Jolly Mazumdar, Anne-Marie Martin, Georgina V. Long, Jennifer Carver
Publikováno v:
Clinical Cancer Research. 22:567-574
Purpose: Tumor-derived circulating cell–free DNA (cfDNA) is a potential alternative source from which to derive tumor mutation status. cfDNA data from four clinical studies of the BRAF inhibitor (BRAFi) dabrafenib or the MEK inhibitor (MEKi) tramet
Autor:
Richard V. Benya, Myra Arcilla, Vanessa Wong, Eva Szabo, L.M. Rodriguez, Asmita Bhattacharya, Zhiliang Huang, Rachel Gonzalez, Steven M. Lipkin, Daniel L. Gillen, Jason A. Zell, Jinah Chung, Robert Carroll, Allen Mo, Frank L. Meyskens, Chris Tucker, Timothy R. Morgan, Daniel W. Rosenberg, Wen-Pin Chen
Publikováno v:
Cancer Prevention Research. 8:222-230
Colorectal cancer progresses through multiple distinct stages that are potentially amenable to chemopreventative intervention. Epidermal growth factor receptor (EGFR) inhibitors are efficacious in advanced tumors including colorectal cancer. There is
Autor:
Thahir Farzan, Kimberly R. Kalli, Paul Haluska, Marc A. Becker, S. John Weroha, Tai W. Wong, Sean C. Harrington, James Krempski, Xiaonan Hou
Publikováno v:
Molecular Cancer Therapeutics. 12:2909-2916
Ovarian cancer mortality ranks highest among all gynecologic cancers with growth factor pathways playing an integral role in tumorigenesis, metastatic dissemination, and therapeutic resistance. The HER and VEGF receptor (VEGFR) are both overexpressed